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Abstract
Background: Primary non-Hodgkin lymphoma (NHL) of the breast represents 0.04–0.5% of
malignant lesions of the breast and accounts for 1.7–2.2% of extra-nodal NHL. Most primary cases
are of B-cell phenotype and only rare cases are of T-cell phenotype. Anaplastic large cell lymphoma
(ALCL) is a rare T-cell lymphoma typically seen in children and young adults with the breast being
one of the least common locations. There are a total of eleven cases of primary ALCL of the breast
described in the literature. Eight of these cases occurred in proximity to breast implants, four in
relation to silicone breast implant and three in relation to saline filled breast implant with three out
of the eight implant related cases having previous history of breast cancer treated surgically.
Adjuvant postoperative chemotherapy is given in only one case. Secondary hematological
malignancies after breast cancer chemotherapy have been reported in literature. However in
contrast to acute myeloid leukemia (AML), the association between lymphoma and administration
of chemotherapy has never been clearly demonstrated.
Case Presentation: In this report we present a case of primary ALCL of the breast arising in
reconstruction mamoplasty capsule of saline filled breast implant after radical mastectomy for
infiltrating ductal carcinoma followed by postoperative chemotherapy twelve years ago.
Conclusion: Primary ALK negative ALCL arising at the site of saline filled breast implant is rare.
It is still unclear whether chemotherapy and breast implantation increases risk of secondary
hematological malignancies significantly. However, it is important to be aware of these
complications and need for careful pathologic examination of tissue removed for implant related
complications to make the correct diagnosis for further patient management and treatment. It is
important to be aware of this entity at this site as it can be easily misdiagnosed on histologic
grounds and to exclude sarcomatoid carcinoma, malignant melanoma and pleomorphic sarcoma by
an appropriate panel of immunostains to arrive at the correct diagnosis of ALCL.
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Primary non-Hodgkin lymphomas (NHL) of the breast
are uncommon. NHLs of the breast represent 0.04–0.5%
of malignant lesions of the breast and account for 1.7% to
2.2% of extra-nodal NHLs [1,2]. Most primary cases are B-
cell phenotype and are more common on the right side
with only rare cases showing a T-cell phenotype. The pri-
mary lymphomas have been defined by the criteria of
Wiseman and Liao, which have been followed by most of
the authors with minor modification [3].
Anaplastic large cell lymphoma (ALCL) is a rare T-cell
lymphoma typically seen in children and young adults. It
has been described in numerous sites; however the breast
is one of the least common locations. Secondary hemato-
logical malignancies after breast cancer chemotherapy
have been reported in the literature [4,5]. Acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS)
are the common hematological disorders associated with
breast cancer chemotherapy [5].
In this report we describe a case of ALCL of the left breast
arising in reconstruction mammoplasty capsule of saline
filled breast implant after radical mastectomy for infiltrat-
ing ductal carcinoma followed by post-operative chemo-
therapy twelve years ago.
Report of a case
This is a 66 years old woman who had a left modified rad-
ical mastectomy in 1994 for infiltrating ductal carcinoma
followed by post-operative chemotherapy. In 1999 she
underwent breast reconstructive surgery with insertion of
a saline filled breast implant. The implant was symptom
free until March 2006 when the patient started to com-
plain of pain at the site of the implant with deviation of
the implant toward the axilla.
On examination there were no signs of infection, break-
down or ulceration but there was tenderness and some
erythema. The implant was properly sized with grade II
capsular contraction. There was no evidence of any mass
along the mastectomy scar or any mass outside the cap-
sule or axillary adenopathy. Mammogram and breast
ultrasound did not show any evidence of recurrent malig-
nancy but did show partial deflation of the implant with
capsular contraction.
Taking into account the pain and the capsular contraction,
the patient underwent capsulectomy with removal of the
implant and insertion of a new implant. At the time of
operation, an irregular mass with some necrosis was iden-
tified medially at 9 o'clock position. Intraoperative biopsy
was taken and a frozen section was done. Frozen section
showed large pleomorphic cells consistent with malig-
nancy; hence the surgeon proceeded with excision of the
whole mass with removal of the implant and the capsule
on which a diagnosis of Primary ALCL was made.
Radiological studies of the chest, abdomen and the pelvis
were clear. Bone marrow core examination was negative.
The patient was treated with three cycles of CHOP chem-
otherapy regimen and also received external beam field
radiation. The patient is alive until the current date with
no evidence of disease.
The excision specimen of the left breast capsulectomy
specimen was fixed in 10% buffered formalin and sec-
tions from paraffin wax embedded tissue blocks were
stained with hematoxylin & eosin (H&E).
Immunohistochemistry was performed using standard
labeled Strep-Avidin-Biotin Technique (LSAB) using the
following antibodies: LCA, AE1AE3, CAM5.2, EMA, CK7,
CK20, 34BE12, Vimentin, CD20, CD79A, CD3, CD5,
CD7, CD4, CD8, CD15, CD30, CD1A, CD21, CD23, ALK-
1, Myeloperoxidase, CD117, EBV-LMP, Fascin, CD56,
IgA, CD34, CD31, Factor VIII, S-100 protein, PNL2,
Melanoma Cocktail, CD68, PLAP, Desmin, Alpha-1 Anti-
trypsin, Alpha-1 Antichymotripsin, Factor X111A.
Molecular analysis was performed for B and T cell gene
rearrangement using standard polymerase chain reaction
(PCR).
Microscopic examination of the H&E stained sections
showed diffuse sheets of large atypical cells having bulky
eosinophilic to foamy/vacuolated, amphophilic cyto-
plasm. The nuclei were large and pleomorphic with vesic-
ular chromatin and prominent one to two nucleoli.
Numerous pleomorphic multinucleate giant cells, binu-
cleate cells, mononucleate cells and cells with horseshoe-
shaped and reniform nuclei with prominent nucleoli were
present (Figs 1A, B, C, D). There was brisk mitotic activity
and areas of necrosis. The tumor cells were infiltrating adi-
pose tissue but did not demonstrate angiotropism or angi-
odestruction. The background showed numerous
histiocytes, eosinophils, plasma cells and neutrophils.
Based on the morphological features, the differential diag-
nosis included sarcomatoid/anaplastic carcinoma, malig-
nant melanoma, pleomorphic sarcoma NOS and
hematological neoplasms such as Hodgkin's lymphoma
and the rare ALCL.
Immunohistochemistry demonstrated that the large atyp-
ical neoplastic cells were focally positive for LCA (Fig 2A)
and EMA (Fig 2B) and strongly positive for CD30 (Fig 2C)
and Vimentin. The tumor cells were negative for all other
markers including ALK-1 (Fig 2D). The background reac-
tive lymphocytes showed positivity for T-cell markers withPage 2 of 6
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cytes stained positive for histiocytic markers.
Molecular analysis by PCR on DNA extracted from the
paraffin embedded tissue showed a monoclonal T-cell
gene rearrangement for the joining and variable regions of
the T-cell gamma receptors with V-gamma I and V-gamma
II primers.
Based on the histology and ancillary tests a diagnosis of
primary ALK negative ALCL, T-cell phenotype was made
on the specimen and other entities considered in the dif-
ferential diagnosis were excluded.
Discussion
Primary NHL of the breast is rare and represents 0.04% to
0.5% of all malignant breast tumors and accounts for
1.7% to 2.2% of extra-nodal NHLs [1,2]. Most cases are of
B-cell phenotype and are more common on the right side
with rare cases showing T cell phenotype. The primary
lymphomas have been defined by the criteria of Wiseman
and Liao as follows:
1. Technically adequate specimen.
2. Mammary tissue and lymphomatous neoplasms in
close association.
3. No evidence of concurrent wide spread disease (as
evidenced by clinical presentation, radiologic studies
and in more recent cases magnetic resonance imaging
study).
4. No prior diagnosis of extra mammary lymphoma
[3].
A, B, C and DFigure 1
A, B, C and D. Pleomorphic large cells infiltrating the implant capsule in solid sheets. H&E ×100 (A) and showing areas of 
necrosis H&E × 200(B), Pleomorphic large cells in an edematous background present singly and in small clusters mimicking a 
carcinoma. H&E × 200 (C), Pleomorphic cells with anaplastic nuclei with prominent nucleoli in a background of inflammatory 
cells. H&E ×400 (D).Page 3 of 6
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kin lymphoma and involves both lymph nodes and extra-
nodal sites. Extra-nodal ALCL has been found in the skin
(21%), soft tissue (17%), bone (17%), lung (11%), and
liver (8%). Involvement of the breast is rare in primary
ALCL [6].
Two clinical forms of the disease have been described, the
more common systemic form accounts for 3% of all adult
non-Hodgkin lymphoma, and the less common cutane-
ous form accounts for 25% of all primary cutaneous lym-
phomas. Although both forms express CD30, systemic
ALCL is the only one that expresses ALK-1 and shows the
characteristic balanced translocation; t [2,5] in the major-
ity of cases [6,7].
There are a total of eleven cases of primary ALCL of the
breast previously reported in the literature [8-17]. Eight of
these cases occurred in proximity to breast implants; five
in relation to silicone implant, three in relation to saline
filled implant similar to our case, with previous history of
breast cancer in four of the eight cases. These four cases
were treated surgically with adjuvant postoperative chem-
otherapy given in only one case and none of these cases
had received radiotherapy [8-11,15].
The clinical presentation of ALCL is usually a mass, which
is sometimes painful [18]. In contrast, patients who devel-
oped breast lymphoma in proximity to breast implant
usually presented with implant-related symptoms with or
without a mass lesion [9]. Our case, presented with
implant related symptoms without mass lesion. There-
A, B, C, and DFigure 2
A, B, C, and D. Tumor cells positive for immunostain for LCA × 200 (A), Tumor cells positive for immunostain for EMA × 
200 (B), Tumor cells positive for immunostain for CD30 × 200 (C), Tumor cells negative for immunostain for ALK-1 × 200 
(D).Page 4 of 6
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examination of tissue removed for implant related com-
plications.
Since eight out of the eleven cases of primary ALCL
occurred in relation to breast implants, it is possible that
there is a relation between the nature of the implant and
the risk of occurrence of lymphoma. Despite early reports
that silicone was biologically inert in human tissue, the
safety of breast implant for augmentation mammoplasty
has been a subject of much discussion with respect to
local and systemic complications, including carcinogenic
effects. An Independent panel of US scientists convened
and concluded that silicone breast implant do not cause
any systemic disease, but these implants can leak and rup-
ture, causing local problems such as scarring, infection
and disfigurement. [8,19,20]. The four cases of ALCL of
the breast that occurred in proximity to a silicone breast
implant among more than one million women with
breast implants, raises the possibility that the occurrence
of lymphoma in those women may not be related directly
to the implant and other unknown factors may have con-
tributed to the development of lymphoma in these
patients [8]. However, in a recent study from Netherlands,
eleven cases of primary breast ALCL were described over a
period of 17 years where five out of the eleven cases
occurred in relation to silicone breast implant performed
for cosmetic reasons. There was no history of cancer,
chemo or radiotherapy. In this study the odds ratio of
ALCL associated with breast prostheses was 18.2, however
the absolute risk was very low due to the rare occurrence
of ALCL of the breast [21].
The risk of developing a primary hematological malig-
nancy in patients with breast cancer treated with post-
operative chemotherapy is approximately 1.5% and the
cumulative risk increases by 0.25–1% for the first 8 years
after treatment. There are several reported cases of AML
and MDS arising in patients with breast cancer treated
post-surgery with chemotherapy and radiotherapy [5].
There is one case series of six patients developing second-
ary hematological malignancies after systemic chemother-
apy for breast cancer of which two developed AML, one
developed MDS, and 3 developed NHL (Diffuse large B
cell lymphoma, Angio-immunoblastic T cell lymphoma
and Mantle cell lymphoma respectively in nodal sites)
[4,22]. There are random case reports on occurrences of
secondary hematological malignancies other than AML
and MDS [22,23]. In contrast to AML, the association
between hematological malignancies and the administra-
tion of chemotherapy has never been clearly demon-
strated. In this particular case, the ALCL is present at the
site of the saline filled breast implant and the patient
underwent treatment with adjuvant chemotherapy post-
surgery for infiltrating ductal carcinoma 12 years ago.
ALCL shows a spectrum of morphologic features depend-
ing on the histologic types. To date three distinct histo-
logic types have been described. These include the
common, lymphohistocytic and small cell variant. Other
less recognized descriptive subtypes include neutrophils
rich, Hodgkin like and sarcomatoid variants [7]. Com-
mon to all these subtypes, is the presence of the character-
istic hallmark cell, which is a large atypical cell with
abundant cytoplasm and eccentric horseshoe shaped or
reniform nuclei. These cells often have an eosinophilic
region near the nucleus and prominent central nucleolus
[6]. Our case could be best classified as lymphohistocytic
subtype. Given the patient's previous history and present
histology, it is important to exclude sarcomatoid carci-
noma, malignant melanoma and pleomorphic sarcoma
by an appropriate panel of immunostains to arrive at the
correct diagnosis of ALCL, as this is a rare a rare entity and
can be easily misdiagnosed.
Preliminary data shows that ALK-1 positivity is one of the
most important predictors of prognosis in ALCL and is
associated with favorable prognosis. In the eleven primary
cases of ALCL, two cases were ALK-1 positive, [12,13] six
were ALK-1 negative and in the remaining three cases the
result of ALK was not known [9,11,14-17]. Our case was
ALK negative and by molecular analysis demonstrated a T-
cell phenotype. Due to the small number of cases identi-
fied in the breast, together with the limited follow up data
and the unknown status of ALK-1 reactivity in some of the
cases, it is difficult to predict the course of primary CD30
positive ALCL of the breast.
Conclusion
In conclusion, we describe a case of primary ALK negative
ALCL arising in the site of saline filled left breast implant
12 years after the patient underwent modified radical
mastectomy followed by adjuvant chemotherapy for infil-
trating ductal carcinoma of the breast. It is still unclear
whether chemotherapy and breast implantation increases
risk of secondary hematological malignancies signifi-
cantly. However, it is important to be aware of these com-
plications and need for careful pathologic examination of
tissue removed for implant related complications to make
the correct diagnosis for further patient management and
treatment. It is therefore important for surgical patholo-
gist to be aware of this entity at this site, as it can be easily
misdiagnosed on histologic grounds.
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